Patent Number: 8,580,493

Title: Screening for compounds that modulate GPR3-mediated beta-arrestin signaling and amyloid beta peptide generation

Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders.

Inventors: De Strooper; Bart (Leuven, BE), Thathiah; Amantha (Leuven, BE)

Assignee: VIB VZW

International Classification: C12Q 1/68 (20060101); C07K 5/00 (20060101); G01N 33/48 (20060101)

Expiration Date: 2022-11-12 0:00:00